AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04491071 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Background questionnaire
Description: questionnaire on the living conditions, socio-professional contexts and environmental conditions of the participants
Study NCT04491071 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Impact of COVID-19 questionnaire
Description: status of the patient with regard to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus)
Study NCT04491071 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Confinement and Communication During the COVID-19 Pandemic
Description: know the experience of containment and isolation during the pandemic
Study NCT04491071 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Mental Health questionnaire
Description: welfare effect
Study NCT04491071 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Patient Health Questionnaire (PHQ-9)
Description: assess depression during the pandemic
Study NCT04491071 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Post Traumatic Stress Disorder questionnaire (PTSD-8)
Description: Assessing the trauma of subjects during the pandemic
Study NCT04491071 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Experiences in Close Relationship Scale questionnaire (ECR-S)
Description: Measuring social ties and attachment of subjects
Study NCT01452100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Patients enrolled into the study will be treated with prednisone, 20 mg/day (if body weight \<70 kg ; or 25mg/d if body weight >70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
Study NCT01452100 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: • Patients enrolled into the study will be treated with placebo, 20 mg/day (if body weight \<70 kg ; or 25mg/d if body weight >70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
Study NCT02914002 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Description: A mobile kitchen visits the 16 selected communities every 2 weeks for a period of 1 year. A 30 minute cooking lesson is given by a trained instructor, the recipes have been designed to be quick and easy to make, use local and inexpensive ingredients, contain mostly vegetables and have a good taste. During the lesson, healthy habit and cooking tips are mentioned as well as the importance of cooking at home and having family meals . A printed version of the recipe is given to every participant. Every session participants are encouraged to prepare the recipe. At the end of the lesson all the participants get to taste the meal and express their opinion.
Study NCT00630383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Hookworm Larvae
Description: 25 live hookworm will be applied to the arm and will infect transdermally. They will be eradicated after 48 weeks.
Study NCT00630383 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Histamine
Description: 0.01% histamine solution is pipetted onto a plaster dressing.
Study NCT04516785 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FIT and VOC
Description: Stool sample (FIT) analysed for blood in faeces and urine sample (VOC) analysed for the presence of volatile organic compounds
Study NCT02466659 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CIAO therapy Amblyz glasses
Description: 3-hour CIAO Therapy Amblyz glasses
Study NCT04911985 — intervention group
Intervention type: DEVICE
Intervention: Measurement of the Cardiac Output/ Cardiac Index
Description: Semiinvasive Measurement of the Cardiac Output/ Cardiac Index with the Pulsion device
Study NCT05427617 — intervention group
Intervention type: DRUG
Intervention: Control group
Description: Physician chosen treatment
Study NCT05427617 — intervention group
Intervention type: DRUG
Intervention: Case group
Description: Druggable ctDNA alterations-guided therapy
Study NCT01626937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non invasive ventilation
Description: After nebulisation of bronchodilatators and administration of corticosteroid therapy, non invasive positive pressure ventilation will be started out of hospital and continuously in COPD patient with acute respiratory distress and respiratory acidosis, using a facial mask, with initial level of inspiratory pressure at 8 mmHg then according to VTe and/or respiratory rate; expiratory pressure at 4 mmHg then according to persistance of inspiratory work, level of FiO2 for an objective of SpO2 between 88 and 92%. In case of failure, NIV will be stopped and endotracheal intubation realized if indicate.
Study NCT01626937 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional medical treatment
Description: Conventional medical treatment includes nebulization of bronchodilatators every 15-20 minutes until hospital and corticosteroid therapy. If indicate during out of hospital setting, endotracheale intubation will be realized. After admission in hospital, non invasive ventilation could be started.
Study NCT02685982 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rhythmic Sensory Stimulation
Description: The stimulation consists of 30 minutes of daily stimulation with specially composed relaxing music tracks embedded with gamma frequency sounds of 30-70 Hz range.~In this study, the stimuli will be delivered with a portable sound device called Sound Oasis Vibroacoustic Therapy System (VTS-1000) unit, which is a low-voltage consumer product that has two built in mid to high frequency speakers and one built in low frequency (subwoofer-type) speaker. The low frequency sounds played by the subwoofer speaker is experienced as vibrotactile vibration. Although the Intervention of Interest in this study is the Rhythmic Sensory Stimulation with low-frequency sounds, the efficacy of the Sound Oasis VTS-1000 device to deliver the intervention will also be subject to observation.
Study NCT00934440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: * First treatment: 10 milligram per kilograms (MG/KG) intravenously (IV) on Day 1every two weeks over 90 minutes.~* Second treatment: 10 MG/KG IV on Day 1 every two weeks over 60 minutes.~* Third and subsequent treatments: 10 MG/KG IV on Day 1 every two weeks over 30 minutes (minimum of two cycles).
Study NCT00934440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: * Dose level 1: 35 mg/m2/day for 7 days.~* Dose level 2: 55 mg/m2/day for 7 days.~* Dose level 3: 75 mg/m2/day for 7 days.~  * mg/m2/day = dose based on height and weight
Study NCT01748240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine and oral vorinostat
Description: In patients still responding after six cycles, the drugs will continue to be supplied, and follow up until death or unacceptable tolerance will be continued in all patients.
Study NCT02540278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Prevention PLUS
Description: PP+ has elven 45 minute lessons: (1) Getting Started, (2) Life Planning, (3) Healthy Relationships, (4) Relationship Violence, (5) Family Planning and Contraceptives, (6) Myths and Stereotypes, (7) HIV Disease and AIDS, (8) Recognizing and Reducing Risk, (9) Peer and Media Pressures, (10) Human Immunodeficiency Virus (HIV)/Sexually Transmitted Disease (STD) Testing and Community Resources, and (11) Steps to Success.
Study NCT03248349 — intervention group
Intervention type: DRUG
Intervention: Pharmacokinetics
Description: * Blood samples are drawn for pharmacokinetic properties of antibiotics during routine care treatment~* Blood samples for relevant covariates of drug disposition (kidney function, liver enzymes, C-reactive protein (CRP), albumin)~* Whole blood is stored for DNA analysis~* Urine is drawn from catheter for more detailed estimation of glomerular filtration rate and drug metabolite analysis
Study NCT03396952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Given PO
Study NCT03396952 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT03396952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03396952 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT00597597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: During the treatment period, subjects will receive single agent erlotinib, 150mg/day.
Study NCT00461071 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guided Self-help for Bulimia nervosa
Description: bibliotherapy
Study NCT02249000 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIOVALVE prosthesis
Description: Transcatheter Aortic Valve Replacement (TAVR)
Study NCT04109885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracervical injection
Description: 1.5 mL of 0.5% bupivacaine will be will be injected bilaterally in the paraspinal musculature of the cervical spine.
Study NCT04109885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prochlorperazine and diphenhydramine.(Standard Treatment)
Description: Intravenous administration of prochlorperazine and diphenhydramine.
Study NCT02447315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral
Study NCT01402297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apocynin and placebo nebulization
Description: 6 ml of apocynin of total dose 3 mg (0.5 mg/ml dissolved in sterile 0.9% NaCl as the study drug) and 0,9% NaCl as placebo, has been nebulized for 15-20 min through the mouthpiece with using of a nose clip. A nebulizer Pulmo Aide AP-50 (DeVilbiss; Richmond, VA) was used (mass median aerosol diameter 3.1 mm, output 0.3 ml/min.)
Study NCT01430650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral strogen
Description: 2 mg of estradiol every day beginning the second day of the cycle until day 7. 4 mg of estradiol every day beginning 8th day of the cycle until day 10. 6 mg of estradiol every day beginning 11th day of the cycle until day 16.
Study NCT01430650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal strogen
Description: One patch of 75 mcg of estradiol hemimydrate every 48 h from 2 to day 6. Two patches of 75 mcg of estradiol hemimydrate every 48 h from 6 to day 12. Three patches of 75 mcg of estradiol hemimydrate every 48 h from 12 to day 16.
Study NCT01505907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXB909
Description: CXB909
Study NCT04537689 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Ixekizumab for 6 months, given 160mg at weeks 0, followed by 80mg at 2, 4, 6, 8, 10 and 12, then 4 weekly till 6 months. Given subcutaneously.
Study NCT04537689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Oral tablet up to 15mg per week
Study NCT04537689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin A
Description: Oral capsule up to 200mg per day
Study NCT04537689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acitretin
Description: Oral capsule up to 25mg per day
Study NCT00145977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: alendronate 70 mg once weekly
Study NCT00145977 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Citrate
Description: 600 mg of calcium citrate
Study NCT00145977 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Citrate
Description: 600 mg of calcium citrate
Study NCT00145977 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 500 mg of Vitamin D consumed with the evening meal.
Study NCT00145977 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 500 mg of Vitamin D consumed with the evening meal.
Study NCT01212380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib
Description: Given IV infusion lasting 30 minutes. Will be administered IV at a specified dose in mg/m2 QDx2 weekly for 3 weeks (days 1, 2, 8, 9, 15, and 16). The first and second dose will always be administered at 20 mg/m2.
Study NCT01212380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytokine Assessment
Description: TNF-α,IFN-γ,IL-6,IL-8,IL-10,and IL-1β pre-dose, completion, 30 minutes, 2 hours, 6 hours, and approximately 24 hours from initiation of therapy on days 1 and 8 of treatment. These will be assessed utilizing standard ELISA or flow cytometry methodology. Other cytokines or soluble factors may be assessed that relate to drug toxicity or response. After 6 patients are examined in each group, the time points or number of cytokines examined may be changed to decrease time points examined. Cytokines will be examined by a multiplex flow cytometry assay or ELISA. Other cytokines, chemokines, or soluble factors may be assessed on residual material not used for these studies.
Study NCT01212380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacodynamic Studies
Description: Based upon our preliminary data changes occuring in vivo during carfilzomib treatment will be determined and if their occurrence correlates with both clinical response and development of cytokine release. These studies will be performed from CD19 selected CLL cells at screening, pre-treatment, 4 hours, and 24 hours post-therapy on days 1 and 8 of treatment; end of therapy evaluation, and at time of relapse (in responding patients). These studies will include assessment of NF-κB (p50/p65 binding; I-κB level, P-I-κB level, select target genes), p53 (p53 nuclear levels, p53 nuclear binding, and select target genes), p73, and ER stress response. Standard Western Blot, EMSA, RT-PCR will be done to complete these studies.
Study NCT01212380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proteosome Inhibition Assessment
Description: Proteosome inhibition on CLL cells will be examined at screening, pre-treatment and post-treatment (immediately after completion of drug) days 1, pre-treatment day 2, day 3 (optional), day 5 (optional),pre and post-treatment days 8, pre and post-treatment days 9, day 10 (optional),day 12 (optional), and day 15 (optional).
Study NCT01212380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Studies
Description: Germ line DNA from a buccal swab and bone marrow fibroblasts will be obtained at baseline screening for possible examination of SNP polymorphisms that may correlate with response and toxicity to carfilzomib therapy. Tumor DNA will be derived from samples obtained at baseline for the p53 mutational studies. SNPs related to drug metabolism, response, or toxicity to therapy, cytokine release, and tumor biology may be examined. Other SNPs may be used in the future. Given the potential for contamination in the recipient, recipient DNA from a buccal swab and/or saliva will be obtained at baseline screening for examination of SNP polymorphisms that may correlate with response, toxicity, and pharmacokinetics.
Study NCT00838032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine fumarate
Description: Quetiapine fumarate should be initiated on Day 1 and titrated to at least 600 mg/day before Day 7 according to clinical experience and prescribe information. After Day 7, the dose of quetiapine fumarate should be adjusted between 600 mg/day to 750 mg/day at the discretion of the investigator.
Study NCT00838032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Haloperidol should be initiated with the dose range from 5 mg/day to 15 mg/day from Day 1 to Day 5 (using injection) according to the clinical experience and prescribe information. After Day 7, the dose of haloperidol should be adjusted between 8 mg/day to 20 mg/day (change from injection to oral formulation between Day 6 to Day 7) at the discretion of the investigator.
Study NCT02027090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Routine dose icotinib
Description: Icotinib is administered 125 mg three times daily.
Study NCT02027090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Higher dose icotinib
Description: After 8-week induction of icotinib with a dose of 125 mg three times daily, icotinib is administered 375 mg three times per day.
Study NCT04792242 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cv line insertion
Description: Svo2 and central venous pressure measurements
Study NCT04792242 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Urinary catheter insertion
Description: urine output measurement
Study NCT04792242 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arterial line
Description: Arterial blood gases measurment
Study NCT03399201 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: induction with the intravenous anesthetic (Propofol) and maintenance with the inhalational anesthetic (Sevoflurane)
Study NCT03399201 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neuraxial anesthesia
Description: Spinal anesthesia will be applied via the local anesthetic ( Bupivacaine).
Study NCT01646632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise intervention
Description: the experimental intervention included group- based progressive resistance training, balance training, and functional training, two times a week, one hour sessions, lasting 16 weeks.
Study NCT01646632 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle counseling
Description: the control intervention included recreational sessions, including talks, video's, music, board games etc. No physical activity was involved in the control intervention.
Study NCT03399201 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Spirometer
Description: Pulmonary function will be evaluated via the portable spirometer (MIR Spirodoc, Spirodoc®, Roma, Italy)
Study NCT03812822 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insole
Description: Custom-made insoles which support the foot at subtalar neutral position
Study NCT03873090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SBRT
Description: hypofractionated accelerated RT for prostate cancer with FFF (Free Flattened Filter) beam. The schedule will be \[ 4 x 9.5 Gy = 38 Gy \] delivered in 5 alternative days, corresponding to an NTD2 between 95 and 119 Gy for an α/β estimate between 3 and 1.5 Gy.
Study NCT00744042 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: asfotase alfa
Study NCT01559740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: This is being used as the local anesthetic for the TAP blocks at either 0.25% or 0.125%. The block will be done once during the procedure.
Study NCT02717832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyperinsulinemic-euglycemic clamp
Study NCT05800301 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Wharton's jelly derived mesenchymal stemcells
Description: The WJ-MSCs suspension from the culture was delivered to the operating room by cold chain and used within 24 h. A total of 1.5 ml of the WJ-MSC suspension was immediately injected into the deep subtenon space of each eye.
Study NCT05800301 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnovision
Description: Specifically designed helmets producing high-frequency repetitive electromagnetic stimulation (MagnovisionTM, Bioretina Biotechnology, Ankara, Türkiye) stimulated the retinas and visual pathways in both eyes.
Study NCT04620876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bimodal high resolution imaging of the retina
Description: The protocol consists of performing an Optical coherence tomography and Scanning laser ophthalmoscope system using adaptive optics (AO-SLO-OCT).The participant is asked to put his forehead against the temple supports and his chin on a chin rest. The subject will be asked to fix a test pattern in the form of a cross. The pattern is positioned according to the desired eccentricity with respect to the fovea. The actual acquisition lasts a few seconds, possibly repeated to cover the field of the desired eye. The acquisition protocol depends on the subjects, their pathology and the system used; the area examined will be modified on a case by case basis. The total duration of each exam can be estimated at less than half an hour, with frequent breaks.
Study NCT05032469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflexology
Description: Reflexology is a method that creates nervous, hormonal and energetic effects in the body using pressure, rubbing and stretching applied with special hand and finger techniques to reflex points corresponding to all parts, organs and systems of the body in the ears, hands and feet
Study NCT01064375 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tetwtCEA DNA (wt CEA with tetanus toxoid Th epitope)
Description: Two vaccinations at week 0 and 12. Intradermal administration of 400ug DNA/dose with electroporation
Study NCT02234050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Trabectedin will be given as a 24-hour infusion every 3 weeks at a starting dose of 1.5 mg/m2 body surface area (BSA), until one of the treatment withdrawal criteria has been met.
Study NCT02234050 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Local standard of care
Description: Left to the discretion of the investigator